Brain cancer - temozolomide (TA23)
Fast, easy summary view of NICE guidance on 'brain cancers'
People with recurrent brain cancer whose initial chemotherapy treatment has failed (either because it was not effective or because it caused side effects) may be considered for treatment with temozolomide, when
- they have a tumour that it has been shown is malignant through microscopic examination of the tumour cells (at first relapse),
- imaging tests have shown that the tumour has re-occurred or is progressing (imaging tests are used to produce pictures of areas inside the body).),
- they have a Karnofsky performance status greater than or equal to 70. (Karnofsky is a measure given by a health professional to a patients ability to perform certain ordinary tasks: 100 = normal, no complaints, 70 = unable to carry on normal activity, 50 =requires considerable assistance, 40 = disabled, 30 -=hospitalisation recommended)
- it is expected that they will live for 12 weeks or more, at the start of the temozolomide treatment.
Temozolomide is only recommended as the initial chemotherapy treatment for patients with brain cancer when they are taking part in a clinical trial
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: brain cancers
This page was last updated: 02 April 2014
Information for the public
Implementation tools and resources
- None available
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.